Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 07, 2015 1:42 AM ET

Biotechnology

Company Overview of Eleven Biotherapeutics, Inc.

Company Overview

Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its product candidates include EBI-005, a novel interleukin-1 receptor antagonist that is in Phase III clinical program for the treatment of moderate to severe dry eye diseases; and has completed Phase II clinical trial for the treatment of allergic conjunctivitis. The company’s preclinical product candidates comprise EBI-031, a novel inhibitor of the cytokine interleukin-6 for the treatment of retinal dis...

215 First Street

Suite 400

Cambridge, MA 02142

United States

Founded in 2008

21 Employees

Phone:

617-871-9911

Fax:

617-858-0911

Key Executives for Eleven Biotherapeutics, Inc.

Chief Executive Officer, President and Director
Age: 56
Total Annual Compensation: $570.9K
Chief Development Officer
Age: 53
Total Annual Compensation: $198.0K
Chief Scientific Officer
Age: 56
Total Annual Compensation: $402.4K
Compensation as of Fiscal Year 2014.

Eleven Biotherapeutics, Inc. Key Developments

Eleven Biotherapeutics, Inc.(NasdaqGM:EBIO) dropped from Russell 2000 Index

Eleven Biotherapeutics, Inc. will be removed from Russell 2000 Index

Eleven Biotherapeutics, Inc.(NasdaqGM:EBIO) dropped from Russell 3000 Index

Eleven Biotherapeutics, Inc. will be removed from the Russell 3000 Index.

Eleven Biotherapeutics, Inc. Announces Executive Changes, Effective July 3, 2015

Eleven Biotherapeutics, Inc. announced that Gregory D. Perry has resigned as Chief Financial and Business Officer, effective July 3, 2015. John J. McCabe, Eleven’s Vice President of Finance and Business Operations, is promoted to assume the roles of Principal Financial Officer and Principal Accounting Officer, reporting directly to Abbie Celniker, PhD, President and Chief Executive Officer of Eleven Biotherapeutics. John McCabe has served as Vice President of Finance and Business Operations of Eleven since June 2013 and as Treasurer since September 2012. Prior to joining Eleven, Mr. McCabe was Vice President of Finance at Clinical Data, Inc.

Similar Private Companies By Industry

Company Name Region
Quartet Medicine United States
Kenna Technologies, Inc. United States
Ichor Biotechnologies, Inc. United States
AxoTect, Inc. United States
Sentigen BioSciences, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
November 25, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Eleven Biotherapeutics, Inc., please visit www.elevenbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.